Carbamoylphosphonate matrix metalloproteinase inhibitors 3: In vivo evaluation of cyclopentylcarbamoylphosphonic acid in experimental metastasis and angiogenesis

Clinical Cancer Research

Volumn 11, Issue 10, 2005, Pages 3925-3929

  Reich, Reuven ^a   Katz, Yiffat ^a   Hadar, Rivka ^a   Breuer, Eli ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPENTYLCARBAMOYLPHOSPHONIC ACID; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; NEUTROPHIL COLLAGENASE; PHOSPHONIC ACID DERIVATIVE; STROMELYSIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HISTOPATHOLOGY; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MELANOMA; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

ANIMALS; CHEMOTAXIS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHONIC ACIDS;

EID: 18844424018     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1985     Document Type: Article

References (33)

1. Whittaker M, Floyd CD, Brown P, Gearing AJH. Design and therapeutic application of matrix metalloproteinaseinhibitors. Chem Rev 1999;99:2735-76.
2. Giavazzi R, Taraboletti G. Preclinical development of metalloproteases inhibitors in cancer therapy. Crit Rev Oncol Hematol 2001;37:53-60.
3. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001;93:178-93.
4. Lipscomb WN, Strater N. Recent advances in zinc enzymology. Chem Rev 1996;96:2375-433.
5. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001;13:534-40.
6. Borkakoti N. Matrix metalloproteinases: variation on the theme. Prog Biophys Mol Biol 1998;70:73-94.
7. Strater RE, Bender SL. Molecular recognition of protein-ligand complexes: applications to drug design. Chem Rev 1997;97:1359-472.
8. Nabeshima K, Inoue T, Shimao Y, Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 2002;52:255-64.
9. Yu AE, Hewitt RE, Kleiner DE, Stetler-Stevenson WG. Molecular regulation of cellular invasion-role of gelatinaseA and TIMP-2. Biochem Cell Biol 1996;74:823-31.
10. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999;13:781-92.
11. Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP, Boyd MT. Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 2004;10:2832-45.
12. Kayano K, Shimada T, Shinomiya T, et al. Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: possible regulation of pro-MMP-2 activation by TIMP-2. J Pathol 2004;202:403-11.
13. Rocca GL, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 2004;90:1414-21.
14. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004;23:101-17.
15. Johnson WH, Roberts NA, Borkakoti N. Collagenase inhibitors: their design and potential therapeutic use. J Enzyme Inhib Med Chem 1987;2:1-22.
16. Skiles JW, Gonnella NC, Jeng AY. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr Med Chem 2004;11:2911-77.
17. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92.
18. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 2004;9:63-79.
19. Farkas E, Katz Y, Bhusare S, et al. Carbamoylphosphonate based matrix metalloproteinase (MMP) inhibitor metal complexes - solution studies and stability constants. Towards a zinc selective binding group. J Biol Inorg Chem 2004;9:307-15.
20. Breuer E, Salomon CJ, Katz Y, et al. Carbamoylphosphonates - a new class of in vivo active matrix metalloproteinase inhibitors 1. Alkyl- and cycloalkylcarbamoylphosphonic acids. J Med Chem 2004;47:2826-32.
21. Reich R, Thompson EW, Iwamoto Y, et al. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membrane by metastatic cells. Cancer Res 1988;4:3307-12.
22. Yoshida D, Takahashi H, Teramoto A. Inhibition of glioma angiogenesis and invasion by SI-27, an anti-matrix metalloproteinase agent in a rat brain tumor model. Neurosurgery 2004;54:1213-22.
23. Hesling C, D'Incan M, Mansard S, et al. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Br J Dermatol 2004;150:761-7.
24. Mira E, Lacalle RA, Buesa JM, et al. Secreted MMP-9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J Cell Sci 2004;117:1847-57.
25. Kumar M, Liu ZR, Thapa L, Chang Q, Wang DY, Qin RY. Antiangiogenic effect of somatostatin receptor subtype 2 on pancreatic cancer cell line: inhibition of vascular endothelial growth factor and matrix metalloproteinase-2 expression in vitro. World J Gastroenterol 2004;10:393-9.
26. Iijima T, Minami Y, Nakamura N, et al. MMP-2 activation and stepwise progression of pulmonary adenocarcinoma: analysis of MMP-2 and MMP-9 with gelatin zymography. Pathol Int 2004;54:295-301.
27. Okada M, Miyake K, Matsumoto Y, Kawai N, Kunishio K, Nagao S. Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas. J Neurooncol 2004;66:29-37.
28. Miyata Y, Kanda S, Nomata K, Hayashida Y, Kanetake H. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival. Urology 2004;63:602-8.
29. Renkiewicz R, Qiu L, Lesch C, et al. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum 2003;48:1742-9.
30. Egeblad M, Werb Z. New function for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
31. Overall CM, López-Otín C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2:657-72.
32. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003;22:177-203.
33. Margolin L, Fishbein I, Banai S, et al. Metalloproteinase inhibition attenuates neointima formation and constrictive remodeling after angioplasty in rats: augmentative effect of αvβ3 receptor blockage. Atherosclerosis 2002;163:273-81.